Fecal Calprotectin and Ulcerative Colitis Endoscopic Activity Index As Indicators of Mucosal Healing in Ulcerative Colitis

Overview

Journal Intern Emerg Med

Publisher Springer

Specialties Emergency Medicine
General Medicine

Date 2014 Nov 5

PMID 25366383

Citations 8

Authors

Tarang Taghvaei

Iradj Maleki

Farshad Nagshvar

Hafez Fakheri

Vahid Hosseini

Seyed Mohammad Valizadeh

Hassan Neishaboori

Affiliations

Soon will be listed here.

Abstract

Ulcerative colitis (UC) is a chronic, idiopathic, inflammatory large bowel disease with recurrent variable periods of exacerbation. The aim of the current study is to evaluate the correlation of UCEIS with fecal calprotectin (FC) level to assess disease activity in UC patients in order to determine whether FC can prognosticate clinical outcome and disease activity of UC instead of colonoscopic evaluation. Our endoscopic investigations revealed the extension of UC as the following: proctitis (11.6%), procto-sigmoiditis (18.5%), left-sided colitis (15.8%), extensive colitis (11.7%), and normal endoscopy (42.4%). Conclusively, we suggest that FC can be used as a reliable tool to evaluate disease activity in ulcerative colitis patients. Moreover, our findings indicate a significant correlation between FC level and mucosal healing.

Citing Articles

Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.

Huong B, Hien N, Dung N, Quang D, Vinh N, Tu T Med Arch. 2024; 78(2):105-111.

PMID: 38566874 PMC: 10983091. DOI: 10.5455/medarh.2024.78.105-111.

Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis.

Zou F, Wang X, Glitza Oliva I, McQuade J, Wang J, Zhang H J Immunother Cancer. 2021; 9(1).

PMID: 33436487 PMC: 7805368. DOI: 10.1136/jitc-2020-002058.

Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission.

Pop C, Filip P, Diaconu S, Matei C, Furtunescu F Medicina (Kaunas). 2021; 57(1).

PMID: 33396524 PMC: 7823820. DOI: 10.3390/medicina57010031.

Correlation between Clinical Symptoms and Lab Tests with Endoscopic Severity Indexes in Patients with Inflammatory Bowel Diseases.

Soleymani S, Moradkhani A, Eftekhari M, Rahmanian F, Moosavy S Middle East J Dig Dis. 2020; 12(3):162-170.

PMID: 33062221 PMC: 7548093. DOI: 10.34172/mejdd.2020.178.

Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.

Urushikubo J, Yanai S, Nakamura S, Kawasaki K, Akasaka R, Sato K World J Gastroenterol. 2018; 24(38):4384-4392.

PMID: 30344422 PMC: 6189847. DOI: 10.3748/wjg.v24.i38.4384.

References

Travis S, Schnell D, Krzeski P, Abreu M, Altman D, Colombel J . Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013; 145(5):987-95. DOI: 10.1053/j.gastro.2013.07.024. View

Desai D, Faubion W, Sandborn W . Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25(3):247-55. DOI: 10.1111/j.1365-2036.2006.03184.x. View

Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T . Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol. 2010; 45(9):936-43. DOI: 10.1007/s00535-010-0244-2. View

Langhorst J, Elsenbruch S, Mueller T, Rueffer A, Spahn G, Michalsen A . Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis. 2005; 11(12):1085-91. DOI: 10.1097/01.mib.0000187980.08686.18. View

Vermeire S, Van Assche G, Rutgeerts P . Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut. 2006; 55(3):426-31. PMC: 1856093. DOI: 10.1136/gut.2005.069476. View

CARPENTER H, Talley N . The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications. Am J Gastroenterol. 2000; 95(4):878-96. DOI: 10.1111/j.1572-0241.2000.01924.x. View

Tibble J, Bjarnason I . Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2002; 7(4):460-5. PMC: 4688655. DOI: 10.3748/wjg.v7.i4.460. View

Rachmilewitz D . Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298(6666):82-6. PMC: 1835436. DOI: 10.1136/bmj.298.6666.82. View

Nikolaus S, Schreiber S . Diagnostics of inflammatory bowel disease. Gastroenterology. 2007; 133(5):1670-89. DOI: 10.1053/j.gastro.2007.09.001. View

10.

Walsh A, Ghosh A, Brain A, Buchel O, Burger D, Thomas S . Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2013; 8(4):318-25. DOI: 10.1016/j.crohns.2013.09.010. View

11.

Tibble J, Sigthorsson G, Bridger S, Fagerhol M, Bjarnason I . Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119(1):15-22. DOI: 10.1053/gast.2000.8523. View

12.

Cooney R, Warren B, Altman D, Abreu M, Travis S . Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials. 2007; 8:17. PMC: 1919394. DOI: 10.1186/1745-6215-8-17. View

13.

Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos G . Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2007; 103(1):162-9. DOI: 10.1111/j.1572-0241.2007.01556.x. View

14.

Xiang J, OuYang Q, Li G, Xiao N . Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008; 14(1):53-7. PMC: 2673391. DOI: 10.3748/wjg.14.53. View

15.

DHaens G, Sandborn W, Feagan B, Geboes K, Hanauer S, Irvine E . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132(2):763-86. DOI: 10.1053/j.gastro.2006.12.038. View

16.

Bjerke K, Halstensen T, Jahnsen F, Pulford K, Brandtzaeg P . Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut. 1993; 34(10):1357-63. PMC: 1374541. DOI: 10.1136/gut.34.10.1357. View

17.

Bitton A, Peppercorn M, Antonioli D, Niles J, Shah S, Bousvaros A . Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001; 120(1):13-20. DOI: 10.1053/gast.2001.20912. View

18.

Gisbert J, Gonzalez-Lama Y, Mate J . [Role of biological markers in inflammatory bowel disease]. Gastroenterol Hepatol. 2007; 30(3):117-29. DOI: 10.1157/13100073. View

19.

Gisbert J, Bermejo F, Perez-Calle J, Taxonera C, Vera I, McNicholl A . Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009; 15(8):1190-8. DOI: 10.1002/ibd.20933. View

20.

Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich A, Rueffer A . Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007; 56(12):1706-13. PMC: 2095695. DOI: 10.1136/gut.2006.113431. View